Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation & Amortization (2017 - 2025)

Crinetics Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 9 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $3.9 million for Q4 2025, up 39.29% from a year ago — trailing twelve months through Dec 2025 was $3.9 million (up 39.29% YoY), and the annual figure for FY2025 was $3.9 million, up 39.29%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $3.9 million at Crinetics Pharmaceuticals, down from $7.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CRNX hit a ceiling of $9.6 million in Q2 2025 and a floor of $1.1 million in Q4 2023.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $4.1 million (2022), compared with a mean of $4.8 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: tumbled 73.07% in 2023 and later surged 154.55% in 2024.
  • Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization stood at $3.5 million in 2021, then increased by 17.36% to $4.1 million in 2022, then tumbled by 73.07% to $1.1 million in 2023, then surged by 154.55% to $2.8 million in 2024, then skyrocketed by 39.29% to $3.9 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $3.9 million (Q4 2025), $7.0 million (Q3 2025), and $9.6 million (Q2 2025) per Business Quant data.